Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/229880 
Year of Publication: 
2020
Series/Report no.: 
DIW focus No. 6
Publisher: 
Deutsches Institut für Wirtschaftsforschung (DIW), Berlin
Abstract: 
The deployment of a safe and effective vaccine for Covid-19 will be central to lifting containment measures. In a bid to speed up vaccine deployment, governments are entering into 'Advance Purchase Agreements' (APAs) with vaccine companies to secure access to vaccine doses. We document and compare the vaccine procurement strategies of the US and the EU. Most notably, we find that both the US and the EU only secure vaccine doses from developers whose (contracted) production facilities are based in US or EU territory, respectively. Securing vaccine production on home soil is crucial in a crisis because of the ability of governments to implement export restrictions; vaccines produced in a different jurisdiction may be blocked from exiting the region. Thus, only governments who can secure local production will be able to provide a vaccine quickly.
Document Type: 
Article

Files in This Item:
File
Size
329.08 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.